(CG1) Amundi DAX DR - Ratings and Ratios

Exchange: PA • Country: France • Currency: EUR • Type: Etf • ISIN: FR0010655712

CG1: German, Equity, Stocks, Investments, Tracking

Amundi ETF DAX UCITS ETF DR (PA:CG1) is an exchange-traded fund that tracks the Morningstar Germany TME NR EUR index, providing investors with exposure to the German equity market. As a France-based ETF, it falls under the Germany Equity category, allowing investors to tap into the regions economic performance.

The funds investment objective is to replicate the performance of its underlying index, thereby offering a diversified portfolio of German equities. With Assets Under Management (AUM) totaling 1.206 billion EUR, the ETF demonstrates a significant presence in the market, indicating its appeal to investors seeking German equity exposure.

Analyzing the ETFs technical data, we observe that the last price is 417.60 EUR, which is below the 20-day Simple Moving Average (SMA) of 426.47 EUR, indicating a potential short-term bearish trend. However, the 50-day SMA stands at 406.54 EUR, suggesting a longer-term bullish outlook as the current price is above this average. The 200-day SMA at 375.24 EUR further supports this bullish perspective, as the ETFs price is significantly above this long-term average. The Average True Range (ATR) is 4.92 EUR, representing 1.18% of the last price, indicating moderate volatility.

Considering the fundamental and technical data, a forecast for Amundi ETF DAX UCITS ETF DR can be derived. Given the current price is near the 52-week high of 431.95 EUR and above the 50-day and 200-day SMAs, a potential short-term correction is possible due to the proximity to the 52-week high and being below the 20-day SMA. However, the long-term trend appears bullish. A prudent strategy could involve monitoring the ETFs price action around the 426.47 EUR level (20-day SMA) for potential entry or exit signals. If the ETF can break above this level and sustain it, it may indicate further upside potential. Conversely, a drop below the 406.54 EUR (50-day SMA) could signal a reversal of the longer-term bullish trend.

Investors should closely watch the ETFs price movements in relation to its moving averages and adjust their strategies accordingly. The forecast suggests a cautious optimism, with a potential for further growth if the ETF can maintain its position above key support levels.

Additional Sources for CG1 ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

CG1 ETF Overview

Market Cap in USD 1,392m
Category Germany Equity
TER 0.10%
IPO / Inception 2008-09-16

CG1 ETF Ratings

Growth Rating 76.5
Fundamental -
Dividend Rating 0.0
Rel. Strength 15.1
Analysts -
Fair Price Momentum 430.00 EUR
Fair Price DCF -

CG1 Dividends

Currently no dividends paid

CG1 Growth Ratios

Growth Correlation 3m 72.8%
Growth Correlation 12m 95.2%
Growth Correlation 5y 79.3%
CAGR 5y 13.68%
CAGR/Max DD 5y 0.51
Sharpe Ratio 12m 2.26
Alpha 20.16
Beta 0.558
Volatility 12.59%
Current Volume 1.5k
Average Volume 20d 1.6k
What is the price of CG1 shares?
As of June 16, 2025, the stock is trading at EUR 417.60 with a total of 1,524 shares traded.
Over the past week, the price has changed by -2.70%, over one month by -0.80%, over three months by +1.22% and over the past year by +29.55%.
Is Amundi DAX DR a good stock to buy?
Yes. Based on ValueRay´s Analyses, Amundi DAX DR (PA:CG1) is currently (June 2025) a good stock to buy. It has a ValueRay Growth Rating of 76.50 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CG1 is around 430.00 EUR . This means that CG1 is currently overvalued and has a potential downside of 2.97%.
Is CG1 a buy, sell or hold?
Amundi DAX DR has no consensus analysts rating.
What are the forecasts for CG1 share price target?
According to our own proprietary Forecast Model, CG1 Amundi DAX DR will be worth about 477.9 in June 2026. The stock is currently trading at 417.60. This means that the stock has a potential upside of +14.45%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 477.9 14.4%